Business Wire

CEOs Say They Are Ready to Lead Beyond Business

Share

Egon Zehnder, the world's preeminent executive search and leadership advisory firm, today released the results of its latest Global CEO Survey at the Berlin Global Dialogue, which is taking place under the theme "Building Common Ground."

The survey, which polled more than 470 CEOs from around the world, highlights the unprecedented changes business leaders foresee in the coming decade and, more importantly, their responsibility in addressing complex global challenges:

  • 95% of CEOs expect significant, systemic shifts in the economy, geopolitics, energy and technology over the next decade.
  • 80% of CEOs acknowledge an expanded role beyond leading their companies, positioning themselves as key players in shaping new societal realities.

The majority of CEOs also believe they can find common ground with other stakeholders, with climate change emerging as the top priority (32%), followed by regulating AI (30%) and promoting a fairer global economy (13%).

"Political shifts, including the concerning rise of right-winged movements, are increasingly relevant to CEOs. Promoting dialogue between leaders from business and politics is hence more crucial than ever," said Lars-Hendrik Röller, Founder and Chair of the Berlin Global Dialogue.

When asked about the importance of adaptive skills for the future, CEOs prioritized “cultivating a culture of openness and curiosity” (99%).

"CEOs are embracing a new era of leadership," said Michael Ensser, Global Chair of Egon Zehnder. "They are positioning themselves as key architects of societal progress. As complexity increases, they recognize that fostering curiosity and openness within their organisations will be critical to meeting the challenges ahead."

The full report "The CEO Response" is available for download at: https://www.egonzehnder.com/the-ceo-response

About the Berlin Global Dialogue

The Berlin Global Dialogue unites leaders from business, policy, and academia to develop joint solutions for the most pressing challenges impacting the global economy. Established in 2022, it emerged from the economic, political, and social realities of the twenty-first century. Founded with the mission to strengthen the dialogue between different stakeholders, the annual summit convenes select high-level participants for candid, eye-level exchanges in interactive formats that highlight diverse perspectives and facilitate cross-disciplinary collaboration. Berlin Global Dialogue is embedded in ESMT Berlin, one of Germany’s leading business schools.

https://www.berlinglobaldialogue.org/

About Egon Zehnder

Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. We help organizations get to the heart of their leadership challenges and offer honest feedback and insights to help leaders realize their true being and purpose.

We are built on a foundation that supports partnership in the truest sense of the word and aligns our interests with those of our clients. Our 600 consultants across 65 offices and 36 countries are former industry and functional leaders who collaborate seamlessly across geographies, industries and functions to deliver the full power of the Firm to every client, every time.

We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide executive search, leadership solutions, CEO search and succession, board advisory, and diversity, equity & inclusion.

Our services include discovering leaders, developing leadership, advancing governance, shaping successions and unlocking transformations. We partner with Mobius Executive Leadership to offer highly experiential, personalized and transformational programs for senior leaders.

We believe that together we can transform people, organizations and the world through leadership.

For more information, visit www.egonzehnder.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240930913921/en/

Contacts

Media Relations:
Klara Schroeder, Berlin Global Dialogue, Berlin, klara.schroeder@esmt.org
Stacy Drumtra, Egon Zehnder, Chicago, stacy.drumtra@egonzehnder.com
Martin Klusmann, Egon Zehnder, Berlin, martin.klusmann@egonzehnder.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RSA and Swissbit Announce New Phishing-Resistant Authentication Solution for Security-First Industries1.10.2024 12:00:00 EEST | Press release

RSA, the security-first identity leader and Swissbit, a long-standing leading expert and manufacturer of storage, security, and embedded IoT solutions, announced a new, next-generation hardware authenticator series today designed to protect highly regulated industries. The RSA iShield Key 2 series, powered by Swissbit, will provide financial services, energy, healthcare, and other highly regulated organizations with the highest-level of phishing-resistant, passwordless authentication needed to simplify credential management and drive toward Zero Architecture (ZTA). Optimized for the RSA cloud identity and access management (IAM) platform, RSA® ID Plus, the RSA iShield Key 2 series offers premiere security and unparalleled flexibility. The RSA iShield Key 2 series is available for order now and will ship Q4 2024. “The worst attacks demand the best defenses. That’s why security-first leaders have trusted RSA for decades to defend them from the most damaging cyberattacks. By working with

TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal1.10.2024 11:46:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech focused on using its proprietary GMP compliant technology platform, C-Stem™, to develop life-saving cell therapies, today published an article in Neurotherapeutics, demonstrating the first successful bioproduction of a Parkinson’s Disease cell therapy in a scalable bioreactor, leading to full behavioral recovery 16 weeks after transplantation using a cryopreserved 3D microtissue format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009598667/en/ TreeFrog Therapeutics 10L bioreactor for cell therapy (Photo credits: TreeFrog Therapeutics) The potential of cell therapy for Parkinson’s Disease is well documented – dating back to pioneering studies in the 1980s using fetal cell transplants – and scientific progress over the last decades provides great hope for the future. The emergence of induced pluripotent cells (iPSCs) opened new pathways and solved one of the first ma

Datalec Precision Installations Appoints Peter Cole as Executive Vice President for APAC Region1.10.2024 11:35:00 EEST | Press release

Datalec Precision Installations (DPI), a provider of world-class data centre design, supply, build, and managed services delivering seamless and integrated end-to-end solutions for data centre operators, today announced the appointment of Peter Cole as Executive Vice President for the Asia-Pacific (APAC) region. Based in Singapore, Cole will spearhead DPI's expansion and strategic growth initiatives across APAC's dynamic data centre market, expected to nearly double to $150.59 billion by 2029. Bringing over four decades of experience in the electrotechnical and digital industry, Cole brings a wealth of expertise to his new role. He will oversee all aspects of DPI's APAC data centre business, including strategic planning, operations, and business development. "Peter's extensive experience and deep understanding of the APAC market make him the ideal leader to drive our growth in this critical region," said Danny Keeper, Group Director of DPI. "His proven track record in delivering large-

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells1.10.2024 11:30:00 EEST | Press release

AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a substance with a new and unique mechanism of action (first-in-class) is being investigated. The drug candidate is being studied in patients with solid tumors and lymphomas. This development program builds on AOP Health’s proven success in delivering cancer stem cell targeting agents that address patients’ unmet medical needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241001468319/en/ AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart) Focus on a promising target The new compound, AOP208, targets and blocks a protein on the surface of the cancer stem cell, the serotonin receptor 1B, which may prove to be critical to treat the root cause of the disease. The compound is given orally and was designed and initially

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study1.10.2024 10:15:00 EEST | Press release

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) in patients with mild-to-moderate ulcerative colitis (M2M UC). These results have been published in the Journal of Clinical Medicine.1 UC is a chronic, inflammatory bowel condition which can cause recurring bloody diarrhoea, stomach pain and extreme tiredness.4 Of those living with UC, over 85% have mild-to-moderate disease.5,6,7 Usually 5-ASA compounds are the first-line therapy for people with M2M UC, followed by a stepwise treatment approach in case of non-response or intolerance. There is currently limited guidance on timely escalation and de-escalation of therapies. OPTIMISE was the first major study to investigate whether a T2T approach based on monitoring of non-invasive parameters, such as clinical symptoms and FC, can provide a significantly higher benefit for patients with M2M U

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye